Business Description
Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Staten Island, New York. It focuses on developing a new class of small molecule antibiotics to treat difficult-to-treat bacterial infections caused by priority pathogens. The company's proprietary approach targets the DNA polymerase IIIC enzyme to inhibit DNA replication in Gram-positive bacteria.
Financial Statements
In thousands, USD
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|
| Selling, General & Administrative Expenses | 6,257 | 8,719 | 8,534 | 7,339 |
| Research & Development Expenses | 1,835 | 5,404 | 6,044 | 4,754 |
| Operating Profit | (8,092) | (14,123) | (14,578) | (12,093) |
| Interest and Investment Income | 125 | 20 | — | — |
| Total Non-Operating Income | 125 | 20 | — | — |
| Income Before Provision for Income Taxes | (7,967) | (14,103) | (14,578) | (12,093) |
| Consolidated Net Income | (7,967) | (14,103) | (14,578) | (12,093) |
| Net Income Attributable to Common Shareholders | (7,967) | (14,103) | (14,578) | (12,093) |
| Basic EPS | -5.32 | -17.45 | -23.00 | -22.40 |
| Diluted EPS | -5.32 | -17.45 | -23.00 | -22.40 |
| Basic Weighted Average Shares Outstanding | 1,499 | 808 | 634 | 541 |
| Diluted Weighted Average Shares Outstanding | 1,499 | 808 | 634 | 541 |
| Shares Outstanding | 2,348 | 852 | 688 | 580 |
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|
| Cash and Cash Equivalents | 7,556 | 3,707 | 7,474 | 9,112 |
| Total Cash and Cash Equivalents | 7,556 | 3,707 | 7,474 | 9,112 |
| Other Receivables | 48 | 51 | 129 | — |
| Total Trade Receivables | 48 | 51 | 129 | — |
| Other Current Assets | 85 | 100 | 106 | 265 |
| Total Current Assets | 7,690 | 3,858 | 7,709 | 9,377 |
| Total Assets | 7,690 | 3,858 | 7,709 | 9,377 |
| Accounts Payable | 2,421 | 3,243 | 3,042 | 2,062 |
| Total Current Liabilities | 2,421 | 3,243 | 3,042 | 2,062 |
| Total Liabilities | 2,421 | 3,243 | 3,042 | 2,062 |
| Common Stock | — | — | 14 | 12 |
| Additional Paid-in Capital | 80,555 | 67,936 | 57,871 | 45,944 |
| Retained Earnings | (75,288) | (67,322) | (53,219) | (38,641) |
| Total Common Shareholders' Equity | 5,269 | 615 | 4,667 | 7,315 |
| Total Shareholders' Equity | 5,269 | 615 | 4,667 | 7,315 |
| Total Liabilities and Shareholders' Equity | 7,690 | 3,858 | 7,709 | 9,377 |
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|
| Net Income | (7,967) | (14,103) | (14,578) | (12,093) |
| Share-Based Compensation Expense | 1,570 | 3,436 | 3,766 | 3,302 |
| Changes in Accounts Payable | (409) | 200 | 981 | 1,218 |
| Changes in Other Operating Activities | 18 | 84 | 30 | 30 |
| Cash from Operating Activities | (6,788) | (10,383) | (9,801) | (7,542) |
| Issuance of Common Shares | 10,638 | 6,616 | 8,163 | 3,695 |
| Net Issuance / (Repurchases) of Common Shares | 10,638 | 6,616 | 8,163 | 3,695 |
| Other Financing Activities | (1) | — | — | — |
| Cash from Financing Activities | 10,637 | 6,616 | 8,163 | 3,695 |
| Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash | 3,849 | (3,767) | (1,638) | (3,847) |
Key Metrics & Ratios
| Metric | Value |
|---|---|
| Market Cap | $6M |
| P/E | -0.47x |
| EV/EBITDA | 0.21x |
| Return on Equity | -270.8% |
| Current Ratio | 3.18x |
Margins
Gross margin
—
Operating margin
—
Net margin
—
Quarterly Trend
| Quarter | Revenue | YoY growth | Operating margin | Operating income |
|---|---|---|---|---|
| Q1 2026 | — | — | — | $-2M |
| Q4 2025 | — | — | — | $-2M |
| Q3 2025 | — | — | — | $-2M |
| Q2 2025 | — | — | — | $-2M |
| Q1 2025 | — | — | — | $-2M |
| Q4 2024 | — | — | — | $-3M |
| Q3 2024 | — | — | — | $-3M |
| Q2 2024 | — | — | — | $-4M |
More on Acurx Pharmaceuticals, Inc.
Figures compiled from public company filings.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.